BPMC

Blueprint Medicines (BPMC)

Blueprint Medicines Corporation

から:

Regulatory News

Text Search:

次の項目別のソート:

Non-Regulatory News

Showing the most relevant articles for your search:NASDAQ:BPMC

<< 前へ 1 2 3 4 5 6 7 8 9 10 11 次へ >>

日付	受信時刻	ニュースソース	見出し	コード	企業名
2024/04/11	21 : 00	PR Newswire (US)	Blueprint Medicines to Host Webcast and Conference Call Highlighting Emerging Opportunities for Mast Cell-Targeted Therapeutics	NASDAQ:BPMC	Blueprint Medicines Corporation
2024/04/05	05 : 01	PR Newswire (US)	Blueprint Medicines Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	NASDAQ:BPMC	Blueprint Medicines Corporation
2024/03/12	07 : 27	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:BPMC	Blueprint Medicines Corporation
2024/03/12	07 : 26	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:BPMC	Blueprint Medicines Corporation
2024/03/12	07 : 24	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:BPMC	Blueprint Medicines Corporation
2024/03/12	07 : 23	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:BPMC	Blueprint Medicines Corporation
2024/03/12	07 : 21	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:BPMC	Blueprint Medicines Corporation
2024/03/12	07 : 20	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:BPMC	Blueprint Medicines Corporation
2024/03/12	07 : 19	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:BPMC	Blueprint Medicines Corporation
2024/03/12	07 : 18	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:BPMC	Blueprint Medicines Corporation
2024/03/12	07 : 15	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:BPMC	Blueprint Medicines Corporation
2024/03/07	06 : 25	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:BPMC	Blueprint Medicines Corporation
2024/03/07	06 : 22	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:BPMC	Blueprint Medicines Corporation
2024/03/07	06 : 20	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:BPMC	Blueprint Medicines Corporation
2024/03/07	06 : 19	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:BPMC	Blueprint Medicines Corporation
2024/03/07	06 : 18	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:BPMC	Blueprint Medicines Corporation
2024/03/07	06 : 17	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:BPMC	Blueprint Medicines Corporation
2024/03/07	06 : 16	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:BPMC	Blueprint Medicines Corporation
2024/03/07	06 : 15	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:BPMC	Blueprint Medicines Corporation
2024/03/07	06 : 01	PR Newswire (US)	Blueprint Medicines Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	NASDAQ:BPMC	Blueprint Medicines Corporation
2024/03/07	00 : 41	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:BPMC	Blueprint Medicines Corporation
2024/03/05	08 : 19	Edgar (US Regulatory)	Form 144 - Report of proposed sale of securities	NASDAQ:BPMC	Blueprint Medicines Corporation
2024/03/02	05 : 06	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:BPMC	Blueprint Medicines Corporation
2024/02/29	06 : 03	Edgar (US Regulatory)	Form 144 - Report of proposed sale of securities	NASDAQ:BPMC	Blueprint Medicines Corporation
2024/02/23	22 : 00	PR Newswire (US)	Blueprint Medicines Highlights AYVAKIT® (avapritinib) Long-Term Efficacy and Safety Data and Advances in Mast Cell Disease Research at 2024 AAAAI Annual Meeting	NASDAQ:BPMC	Blueprint Medicines Corporation
2024/02/22	22 : 20	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:BPMC	Blueprint Medicines Corporation
2024/02/22	22 : 20	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:BPMC	Blueprint Medicines Corporation
2024/02/17	06 : 40	Edgar (US Regulatory)	Form S-8 - Securities to be offered to employees in employee benefit plans	NASDAQ:BPMC	Blueprint Medicines Corporation
2024/02/16	07 : 26	Edgar (US Regulatory)	Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]	NASDAQ:BPMC	Blueprint Medicines Corporation
2024/02/15	21 : 05	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:BPMC	Blueprint Medicines Corporation